Rubidium
drugOn this page
Summary
Rubidium (CHEMBL1201326) is an approved small molecule targeting KCNJ2.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Targets: 1 (KCNJ2)
- Clinical trials: 1
- Chemistry: 85.468 Da · Rb
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201326 |
| Name | Rubidium |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 5357696 |
| ChEBI | CHEBI:33322 |
| Molecular formula | Rb |
| Molecular weight | 85.468 |
| InChIKey | IGLNJRXAVVLDKE-UHFFFAOYSA-N |
SMILES: [Rb]
IUPAC name: rubidium
Also known as: Rubidium, RUBIDIUM
Parent form; salt/anhydrous children: CHEMBL4297424
Patent coverage: 3,020 distinct patent families (6,089 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,088 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| KCNJ2 | Kir2.1 | Antagonist | 0% | P63252 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): KCNJ2.
Top Reactome pathways
18 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neurotransmitter receptors and postsynaptic signal transmission | 1 | KCNJ2 |
| Transmission across Chemical Synapses | 1 | KCNJ2 |
| Neuronal System | 1 | KCNJ2 |
| Activation of G protein gated Potassium channels | 1 | KCNJ2 |
| Classical Kir channels | 1 | KCNJ2 |
| G protein gated Potassium channels | 1 | KCNJ2 |
| Inwardly rectifying K+ channels | 1 | KCNJ2 |
| Potassium Channels | 1 | KCNJ2 |
| Muscle contraction | 1 | KCNJ2 |
| Phase 4 - resting membrane potential | 1 | KCNJ2 |
| Cardiac conduction | 1 | KCNJ2 |
| Sensory Perception | 1 | KCNJ2 |
| Sensory perception of taste | 1 | KCNJ2 |
| Sensory perception of sour taste | 1 | KCNJ2 |
| GABA receptor activation | 1 | KCNJ2 |
| GABA B receptor activation | 1 | KCNJ2 |
| Activation of GABAB receptors | 1 | KCNJ2 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 1 | KCNJ2 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| potassium ion transport | 1 |
| regulation of skeletal muscle contraction via regulation of action potential | 1 |
| magnesium ion transport | 1 |
| intracellular potassium ion homeostasis | 1 |
| regulation of monoatomic ion transmembrane transport | 1 |
| protein homotetramerization | 1 |
| relaxation of cardiac muscle | 1 |
| regulation of resting membrane potential | 1 |
| regulation of membrane repolarization | 1 |
| cellular response to mechanical stimulus | 1 |
| potassium ion transmembrane transport | 1 |
| cardiac muscle cell action potential involved in contraction | 1 |
| regulation of cardiac muscle cell contraction | 1 |
| membrane repolarization during action potential | 1 |
| membrane depolarization during cardiac muscle cell action potential | 1 |
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03048097 | EARLY_PHASE1 | COMPLETED | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
3 molecules share ≥1 primary target. Top 3 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Belzutifan | PubChem | Approved | KCNJ2 |
| Propafenone | PubChem | Approved | KCNJ2 |
| Zuranolone | PubChem | Approved | KCNJ2 |
Related Atlas pages
- Genes: KCNJ2
- Drugs: Belzutifan, Propafenone, Zuranolone